产品/疗法

低磷血症作为 CAR-T 细胞接受者免疫效应细胞相关神经毒性综合征的标志物

Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients.

描述 idecabtagene vicleucel 的细胞扩增特征及其与三药暴露复发/难治性多发性骨髓瘤患者临床疗效和安全性的关联

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Re

三类暴露复发/难治性多发性骨髓瘤患者中 idecabtagene vicleucel 的群体细胞动力学

Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

ide-cel 的细胞动力学可通过改良分段模型得到充分描述。

复发/难治性多发性骨髓瘤中 CAR-T 细胞治疗的成功序贯应用

Successful sequential application of CAR T-cell-therapies in relapsed refractory multiple myeloma.

多发性骨髓瘤 CAR-T 细胞治疗综述：加拿大视角

Review of CAR T-Cell Therapy in Multiple Myeloma: A Canadian Perspective.

序贯而非挽救

Sequence not salvage.

Idecabtagene vicleucel（Abecma）用于多发性骨髓瘤

Idecabtagene vicleucel (Abecma) for multiple myeloma.

靶向 B 细胞成熟抗原、抑制多发性骨髓瘤细胞生长的 T 细胞重定向双特异性抗体的开发

Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.

我们的结果提示，FabscFv 形式的 BCMA CD3 双特异性抗体可有效抑制 MM 细胞生长，有望开发成为用于治疗 MM 的治疗性抗体药物。

CAR-T 细胞治疗产品的免疫原性：证据、机制与减轻策略

Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation.

生产工艺对 CAR-T 细胞功能的影响

Impact of Manufacturing Procedures on CAR T Cell Functionality.

利用 CRISPR/Cas9 技术强化 CAR-T 细胞治疗应用

Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology.